Request for Proposals (RFP) Notice: Clinical Research Coordinating Center for NIDA’s Clinical Trials Network

Notice Number: NOT-DA-15-039

Key Dates
Release Date: January 15, 2015

Related Announcements
None

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

THIS REQUIREMENT IS A 100% SMALL BUSINESS SET-ASIDE. The North American Industrial Classification System (NAICS) code applicable to this requirement is 541712.
The National Institute on Drug Abuse (NIDA) plans to solicit proposals from small business concerns having the capability to provide a wide range of clinical trial administrative and research support and related services for multi-site clinical trials conducted within the NIDA Clinical Trials Network (CTN). The awardee will not be responsible for actually conducting clinical trials to be carried out under this contract. A solicitation will be released through the Federal Business Opportunities website (URL: https://www.fbo.gov/). The RFP will be released on or about January 30, 2015 and proposals will be due approximately 45 days thereafter.
Research Initiative Details

Activities under this contract will support the trials carried out under cooperative agreements with CTN grantees located across the nation. The work required under this contract includes:

1) Providing support for regulatory functions and requirements;
2) Reviewing and monitoring protocol implementation;
3) Providing training to research staff;
4) Providing pharmaceutical services and clinical research support;
5) Providing drug testing and analytical laboratory services;
6) Providing support for protocol development;
7) Participating in relevant committee and subcommittee meetings and conference calls;
8) Providing other expert consultation and support services as needed.

It is mandatory that offerors possess a Drug Enforcement Agency (DEA) Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970. In addition, the successful offeror must either possess, or demonstrate the ability to obtain a DEA registration for Schedule I controlled substances.

Inquiries

Please direct all inquiries to:

Jeffrey Schmidt
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6677
Email: schmidtjr@mail.nih.gov